PATIENT Act of 2015 Promoting Access for Treatments Ideal in Enhancing New Therapies Act of 2015
Do you support it?
Want to know if it passes?
We'll email you when HR 1353 moves — a committee vote, a floor vote, or a signature. Nothing else.
Free forever · unsubscribe in one click.
Your answer was recorded either way.
Which district are you in?
Your ZIP is all we need to match you to your own representatives — so we can tell you how they voted on HR 1353.
You're tracking HR 1353
We'll email you the moment it moves.
HR 1353 — PATIENT Act of 2015 Promoting Access for Treatments Ideal in Enhancing New Therapies Act of 2015
Last action — Referred to the Subcommittee on Health.
No card. One bill, free forever — alerts when it moves.
-
✓Introduced
-
✓In Committee
-
Died in session
This bill died with 114th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.
Summary
PATIENT Act of 2015 Promoting Access for Treatments Ideal in Enhancing New Therapies Act of 2015 This bill amends the Federal Food, Drug, and Cosmetic Act to extend to five years the three-year marketing exclusivity period provided to certain new drugs that include an active ingredient that was already approved by the Food and Drug Administration. A drug is provided this extended exclusivity period if it is approved for a new indication or use, or the drug has been reformulated or redesigned to: promote greater patient adherence to an approved treatment regime, reduce the public health risks associated with the drug, reduce side effects or adverse events, provide benefits to the health-care system, or provide other comparable patient benefits.
Bill Text
We don't have the full text on file for this bill yet.
Read HR 1353 on the official United States source →Action History
-
Referred to the Subcommittee on Health.
-
Referred to the House Committee on Energy and Commerce.
-
Introduced in House
Sponsors
- Gus Bilirakis · Primary
Sponsorship breakdown
Export CSV (upgrade) →1 sponsors · 0 co-sponsors · 546 not signed on
Sponsors (1)
Co-sponsors (0)
None.
Not signed on (546)
546 members have not signed on to this bill.
Show all 546 →"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.
Subjects
Frequently asked questions
- What does HR 1353 do?
- PATIENT Act of 2015 Promoting Access for Treatments Ideal in Enhancing New Therapies Act of 2015 This bill amends the Federal Food, Drug, and Cosmetic Act to extend to five years the three-year marketing exclusivity period provided to certain new drugs that include an active ingredient that was already approved by the Food and Drug Administration. A drug is provided this extended exclusivity period if it is approved for a new indication or use, or the drug has been reformulated or redesigned to: promote greater patient adherence to an approved treatment regime, reduce the public health risks associated with the drug, reduce side effects or adverse events, provide benefits to the health-care system, or provide other comparable patient benefits.
- Who sponsors HR 1353?
- HR 1353 is sponsored by Gus Bilirakis (R).
- What is the current status of HR 1353?
- This bill died with 114th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
- Where can I track HR 1353?
- Track HR 1353 free on One Click Politics — get push/email alerts when it moves.
Make your voice heard on HR 1353
Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.
Stay ahead of HR 1353
Last checked for changes about 12 hours ago · updated continuously
One Click Politics tracks every bill in Congress and all 50 states.
Track this bill →